Rivaroxaban and Apixaban

Mechanism

Pharmacologic Class and Drug Group

Antithrombotic agents and anticoagulants belonging to the class of Direct Oral Anticoagulants (DOACs) and Selective Inhibitors of Activated Factor Xa.

Mechanism of Action

The coagulation cascade converges on the common pathway when factor X becomes factor Xa. Factor Xa assembles with factor Va on activated platelet phospholipid membranes to form the prothrombinase, which converts inactive prothrombin into active thrombin (factor IIa), amplifying fibrin formation and clot development.

Molecular Mechanism of Direct Factor Xa Inhibition

1. Direct, competitive and highly reversible inhibition of Factor Xa: Rivaroxaban and apixaban bind directly and selectively to the S1 and S4 pockets of circulating factor Xa and factor Xa in the platelet prothrombinase complex, blocking its catalytic interaction with prothrombin:

DOAC Xa Active Factor Xa ↓ Thrombin Generation Blocking Fibrin Synthesis

2. Buffer effect without cofactor: Unlike low-molecular-weight heparins, which require antithrombin III, factor Xa DOACs act directly on their enzyme target, producing an anticoagulant response independent of circulating cofactor levels.

3. No need for routine monitoring: Predictable anticoagulant responses generally remove the need for routine INR monitoring, as used for vitamin K antagonists such as warfarin. Clinical follow-up and renal function assessment remain necessary.

Pharmacokinetics

High-Resolution Pharmacokinetics

Indicators and dose

Clinical Indications and Uses

• Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation: First-line, demonstrating better or equal efficacy than warfarin with substantially lower rates of intracranial hemorrhage (ROCKET-AF trials for rivaroxaban and ARISTOTLE for apixaban).
• Treatment and Secondary Prevention of Deep Vein Thrombosis (DVT) and Pulmonary Thromboembolism (PTE): Effective and safe therapeutic scheme for initial outpatient management.
• DVT/PTE prophylaxis after Major Orthopedic Surgery: Indicated after elective hip or knee replacements.

Dosage and Clinical Adjustment

Rivaroxaban:

• Prevention of Stroke in AF: 20 mg once a day orally, mandatory administered with dinner to ensure absorption.
• Renal Adjustment in AF: In adult nonvalvular AF, adjust using creatinine clearance (CrCl); do not automatically substitute indexed eGFR. European product information specifies 15 mg once daily with food for CrCl 15–49 mL/min, with caution at 15–29 mL/min. Not recommended below 15 mL/min. Check the jurisdiction-specific product information and indication.

Apixaban:

• Prevention of Stroke in AF: 5 mg twice a day orally continuously.
• AF Reduction Dose Adjustment (To 2.5 mg twice daily): Mandatory if the patient concurrently meets a minimum of two of the following three clinical exclusion criteria:

ABC Criteria for Apixaban Reduction in AF

To ensure safe anticoagulation and prevent severe bleeding in frail patients, reduce the apixaban dose to 2.5 mg twice daily only if at least two of the following conditions are present:

Age ≥ 80 years or Weight ≤ 60 kg or Serum creatinine ≥ 1.5 mg/dL

This dose adjustment clearly reduces the risk of major bleeding in the elderly without significantly compromising the protective efficacy against systemic cerebral embolism.

Security

Absolute and Relative Contraindications

Absolute Contraindications

• Active clinical bleeding of a severe range or pathology of high active bleeding risk.
• End-stage renal disease (eGFR < 15 mL/min/1.73 m² or dialysis): Its use is not generally recommended in terminal stages of loss of glomerular filtration (although apixaban has guidelines for exceptional use at reduced doses in some countries).
• Valvular Atrial Fibrillation (Moderate-Severe Mitral Stenosis or Mechanical Cardiac Prosthesis): The use of DOACs in these patients is associated with catastrophic rates of thrombosis and stroke compared to VKAs.

Relative Contraindications

• Advanced renal impairment: adjustment depends on the drug, indication, creatinine clearance and product information; there is no uniform reduction for all DOACs.
• Moderate hepatic impairment (Child-Pugh Class B) or previous underlying coagulopathy.

Adverse Effects and Toxicity

• Systemic Hemorrhage (main ADR): Major bleeding from the digestive or urinary tract or deep hematomas.
• Anemia secondary to occult bleeding: Requires serial hemoglobin determinations in medical check-ups.
• Moderate thrombocytopenia: Uncommon.

Antidete Alert: Acute Reversal of Anticoagulation by Xa Inhibitors

In severe life-threatening bleeding (such as active intracranial hemorrhage) or unscheduled emergency surgery, rivaroxaban or apixaban anticoagulation requires urgent assessment and a local reversal protocol; andexanet availability and authorization vary by jurisdiction:

Severe bleeding with a factor Xa DOAC: follow the local reversal protocol; andexanet depends on jurisdiction

Andexanet alfa is a modified recombinant human factor Xa molecule lacking catalytic activity while retaining affinity for factor Xa inhibitors. It acts as a molecular decoy, binding and neutralizing free plasma rivaroxaban or apixaban; laboratory reversal does not guarantee immediate hemostasis or eliminate thrombotic risk.

Relevant Drug Interactions

• Potent Dual Inhibitors of CYP3A4 and P-Glycoprotein (Ketoconazole, Itraconazole, Ritonavir): They critically increase the systemic exposure of DOACs Xa, doubling the risk of major spontaneous bleeding. Their joint use is contraindicated.
• Potent Dual Inducers of CYP3A4 and G-gp (Rifampicin, Carbamazepine, Phenytoin): They drastically accelerate the clearance of DOACs, decreasing their effectiveness by up to 50% and severely increasing the risk of ischemic strokes.